OpenBilldrug price receipt

NADAC week of 2026-10-14

ZIPRASIDONE 20 MG/ML VIAL

For 1 unit (EA)

Pharmacies pay

$21.81 filed

1 × $21.8074 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$35.17 filed

1 × $35.17236 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

1.6× estimated

Medicare paid 1.6× what pharmacies pay.

Part D averages every strength and form sold under “Ziprasidone Mesylate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-07-22 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$30.08 estimated

$21.81 + $3.27 (15%) + $5.00 fee per fill = $30.08

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-07-22 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ZIPRASIDONE 20 MG/ML VIAL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ziprasidone mesylate.

FDA gives its dosage form as injection, powder, lyophilized, for solution and its route as intramuscular.

Its labelers, the companies named on the label, are Dr.Reddy's Laboratories, Inc., Novadoz Pharmaceuticals LLC and Fosun Pharma USA Inc.

FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.

The NADAC file of 2026-10-14 prices it under 5 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $21.81 for 1 unit (EA) (1 × $21.8074 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-07-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

The NADAC of all 5 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-07-22. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

All 5 NDCs

Compared with its class

The middle of its 5 NDCs’ NADAC prices is $21.8074 per EA filed.

Of the 130 other products in FDA’s Atypical Antipsychotic class priced per EA, 40 have a higher middle NADAC price and 90 a lower one. The one in the middle is OLANZAPINE-FLUOXETINE 6-25 MG, at $4.05968 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $35.17 for 1 unit (EA), at an average of $35.17236 per EA in 2024 (2024-01-01 to 2024-12-31) for “Ziprasidone Mesylate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 2,734 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for ZIPRASIDONE 20 MG/ML VIAL labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Ziprasidone Mesylate / Ziprasidone Mesylate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.
Why does this page start at 1 unit (EA)?
NADAC prices this product per EA, and the FDA NDC Directory lists its 5 NDCs as dosage form “INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION” with route “INTRAMUSCULAR”. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be a whole package (such as a kit, pen, syringe, vial or inhaler) or one dose inside it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.

Its pharmacologic class

Related in the same class

More